Aduro Biotech, Inc. (ADRO) Insider Elsas Andrea Van Sells 4,922 Shares
Aduro Biotech, Inc. (NASDAQ:ADRO) insider Elsas Andrea Van sold 4,922 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total value of $54,092.78. Following the sale, the insider now owns 212,153 shares of the company’s stock, valued at $2,331,561.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) traded up 0.90% during mid-day trading on Thursday, hitting $11.15. The company had a trading volume of 609,127 shares. The firm’s 50-day moving average price is $11.67 and its 200 day moving average price is $10.97. Aduro Biotech, Inc. has a one year low of $8.75 and a one year high of $15.52. The company’s market capitalization is $831.92 million.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The company had revenue of $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company’s revenue was down 84.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.03 earnings per share. Analysts predict that Aduro Biotech, Inc. will post ($1.37) earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. BidaskClub upgraded Aduro Biotech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Cowen and Company assumed coverage on Aduro Biotech in a report on Tuesday, July 18th. They set an “outperform” rating for the company. Zacks Investment Research upgraded Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, July 4th. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, HC Wainwright set a $18.00 price objective on Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Aduro Biotech has a consensus rating of “Buy” and a consensus target price of $19.00.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its position in Aduro Biotech by 12.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock valued at $388,000 after acquiring an additional 3,769 shares in the last quarter. State Street Corp lifted its position in Aduro Biotech by 8.3% in the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after acquiring an additional 52,597 shares in the last quarter. Nexthera Capital LP bought a new stake in Aduro Biotech in the 2nd quarter valued at $1,767,000. PDT Partners LLC bought a new stake in Aduro Biotech in the 2nd quarter valued at $570,000. Finally, Voya Investment Management LLC lifted its position in Aduro Biotech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 2,515 shares in the last quarter. 35.05% of the stock is currently owned by institutional investors and hedge funds.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.